Coronavirus Vaccine Market Size, Share & Trends Analysis Report By Infection Type (HCoV-229E, HCoV-OC43, SARS-CoV, New Haven CoV, HKU1-CoV, and MERS-CoV), Vaccine Type (Inactivated coronavirus vaccine, Live attenuated coronavirus vaccine, S-Protein based coronavirus vaccine), Region, And Segment Forecasts, 2023-2031.

Report Id: 1019 Pages: 185 Last Updated: 21 November 2024 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Market Segmentation of Coronavirus Vaccine Market

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 based on Infection Type

  • HCoV-229E
  • HCoV-OC43
  • SARS-CoV
  • New Haven CoV
  • HKU1-CoV
  • MERS-CoV

Coronavirus Vaccine Market

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 based on Vaccine Type

  • Inactivated coronavirus vaccine
  • Live attenuated coronavirus vaccine
  • S-Protein based coronavirus vaccine

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 based on End-Users

  • Hospitals
  • Clinics
  • Research Institutes
  • Others

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 based on Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

North America coronavirus vaccine market revenue (US$ Million) by Country, 2020 to 2030

  • U.S.
  • Canada

Europe coronavirus vaccine market revenue (US$ Million) by Country, 2020 to 2030

  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific coronavirus vaccine market revenue (US$ Million) by Country, 2020 to 2030

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America coronavirus vaccine market revenue (US$ Million) by Country, 2020 to 2030

  • Brazil
  • Mexico
  • Rest of Latin America

 Middle East & Africa coronavirus vaccine market revenue (US$ Million) by Country, 2020 to 2030

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Landscape

  • Company Overview
  • Financial Performance
  • Key Development
  • Latest Strategic DevelopmentsLatest Strategic Developments Image

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Coronavirus Vaccine Market Snapshot

Chapter 4. Global Coronavirus Vaccine Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Clinical Trial/Pipeline Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Major Investment, Partnerships and Collaborations in COVID 19 Research

Chapter 5. Market Segmentation 1: By Infection Type, Estimates & Trend Analysis

5.1. By Infection Type, & Market Share, 2020 & 2030

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Infection Type:

5.2.1. HCoV-229E

5.2.2. HCoV-OC43

5.2.3. SARS-CoV

5.2.4. New Haven CoV

5.2.5. HKU1-CoV

5.2.6. MERS-CoV

Chapter 6. Market Segmentation 2: By Vaccine Type Estimates & Trend Analysis

6.1. By Vaccine Type & Market Share, 2020 & 2030

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Vaccine Type:

6.2.1. Protein subunit

6.2.2. Viral Vector (non-replicating)

6.2.3. DNA

6.2.4. Inactivated Virus

6.2.5. RNA

6.2.6. Viral Vector (replicating)

6.2.7. Virus Like Particle

6.2.8. Others

Chapter 7. Market Segmentation 3: By End-Users Estimates & Trend Analysis

7.1. By End-Users & Market Share, 2020& 2030

7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By End-Users:

7.2.1. Hospitals

7.2.2. Clinics

7.2.3. Research Institutes

7.2.4. Others

Chapter 8. Coronavirus Vaccine Market Segmentation 3: Regional Estimates & Trend Analysis

8.1. North America

8.1.1. North America Coronavirus Vaccine Market revenue (US$ Million) estimates and forecasts By Infection Type, 2020-2030

8.1.2. North America Coronavirus Vaccine Market revenue (US$ Million) estimates and forecasts By Vaccine Type, 2020-2030

8.1.3. North America Coronavirus Vaccine Market revenue (US$ Million) estimates and forecasts By End-Users, 2020-2030

8.1.4. North America Coronavirus Vaccine Market revenue (US$ Million) estimates and forecasts by country, 2020-2030

8.2. Europe

8.2.1. Europe Coronavirus Vaccine Market revenue (US$ Million) By Infection Type, 2020-2030

8.2.2. Europe Coronavirus Vaccine Market revenue (US$ Million) By Vaccine Type, 2020-2030

8.2.3. Europe Coronavirus Vaccine Market revenue (US$ Million) By End-Users, 2020-2030

8.2.4. Europe Coronavirus Vaccine Market revenue (US$ Million) by country, 2020-2030

8.3. Asia Pacific

8.3.1. Asia Pacific Coronavirus Vaccine Market revenue (US$ Million) By Infection Type, 2020-2030

8.3.2. Asia Pacific Coronavirus Vaccine Market revenue (US$ Million) By Vaccine Type, 2020-2030

8.3.3. Asia Pacific Coronavirus Vaccine Market revenue (US$ Million) By End-Users, 2020-2030

8.3.4. Asia Pacific Coronavirus Vaccine Market revenue (US$ Million) by country, 2020-2030

8.4. Latin America

8.4.1. Latin America Coronavirus Vaccine Market revenue (US$ Million) By Infection Type, (US$ Million)

8.4.2. Latin America Coronavirus Vaccine Market revenue (US$ Million) By Vaccine Type, (US$ Million)

8.4.3. Latin America Coronavirus Vaccine Market revenue (US$ Million) By End-Users, (US$ Million)

8.4.4. Latin America Coronavirus Vaccine Market revenue (US$ Million) by country, (US$ Million) 2020-2030

8.5. Middle East & Africa

8.5.1. Middle East & Africa Coronavirus Vaccine Market revenue (US$ Million) By Infection Type, (US$ Million)

8.5.2. Middle East & Africa Coronavirus Vaccine Market revenue (US$ Million) By Vaccine Type, (US$ Million)

8.5.3. Middle East & Africa Coronavirus Vaccine Market revenue (US$ Million) By End-Users, (US$ Million)

8.5.4. Middle East & Africa Coronavirus Vaccine Market revenue (US$ Million) by country, (US$ Million) 2020-2030

Chapter 9. Competitive Landscape

9.1. Company Profiles

9.1.1. I-Mab Biopharma

9.1.2. Medicago

9.1.3. Airway Therapeutics

9.1.4. Tiziana Life Sciences

9.1.5. Inovio Pharmaceuticals

9.1.6.  Novavax, Inc

9.1.7. Moderna

9.1.8. AstraZeneca

9.1.9. Pfizer

9.1.10. Johnson &Johnson

9.1.11. GlaxoSmithKline

9.1.12. Bharath Biotech

9.1.13. Serum Institute of India

9.1.14. Sinopharm

9.1.15. AnGes

9.1.16. AIVITABiomedical

9.1.17. CanSinoBio

9.1.18. eubiologics

9.1.19. Genexine

9.1.20. GreenLight Bioscience

9.1.21. Gennova

9.1.22. Heat Biologics

9.1.23. INOVIO

9.1.24. IIBR

9.1.25. medicago

9.1.26. Symvivo

9.1.27. Valneva

9.1.28. Zydus Cadila

9.1.29. CODAGENIX Inc.

9.1.30. Other Prominent Player

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
9492
Security Code field cannot be blank!

Frequently Asked Questions

Key Players of coronavirus vaccine market are I-Mab Biopharma, Medicago, Airway Therapeutics, Tiziana Life Sciences, Inovio Pharmaceuticals, Novavax,

The Coronavirus Vaccine Market is expected to grow at a -25.0 % CAGR during the forecast period for 2023-2031.
Get Sample Report Enquiry Before Buying